Related Experiment Video
Updated: Mar 19, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Opposing Effects of Antidiabetic Interventions on Malignant Growth and Metastasis
Matthias H Tschöp1, Michael Stumvoll2, Michael Ristow3
1Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, 80333 Munich, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
Abstract:
Type 2 diabetes is associated with increased risk of malignancies, whereas antidiabetic interventions like physical exercise or metformin reduce cancer incidence. A recent publication shows that one diabetes treatment approach, namely incretin-related DPP4 inhibitors, increases metastatic capacity by activating the antioxidant transcription factor NRF2 to decrease reactive oxygen species (ROS) levels.
Insights
Type 2 diabetes treatments can impact cancer. Incretin-related DPP4 inhibitors, used for diabetes, may increase cancer metastasis by activating the NRF2 pathway and reducing oxidative stress.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Type 2 diabetes (T2D) is linked to higher cancer risk.
- Some diabetes treatments, like exercise and metformin, lower cancer incidence.
- Incretin-based therapies are a common T2D treatment approach.
Purpose of the Study:
- To investigate the effect of incretin-related DPP4 inhibitors on cancer metastasis.
- To explore the role of the NRF2 pathway in mediating these effects.
Main Methods:
- Analysis of a recent publication on DPP4 inhibitors and cancer.
- Examination of the activation of the antioxidant transcription factor NRF2.
- Assessment of reactive oxygen species (ROS) levels.
Main Results:
- DPP4 inhibitors were shown to increase the metastatic capacity of cancer cells.
- This effect was linked to the activation of the NRF2 pathway.
- NRF2 activation led to decreased levels of reactive oxygen species (ROS).
Conclusions:
- Incretin-related DPP4 inhibitors may promote cancer metastasis.
- The NRF2 pathway and ROS reduction are key mechanisms involved.
- This highlights a potential adverse effect of certain diabetes medications on cancer progression.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Psychoneuroimmunology: Diabetes and Cancer
Drug toxicity: Drug–Drug Interaction
Hypoglycemia and Glucagon

